Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.
Animals
Antigen Presentation
/ immunology
Antigen-Presenting Cells
/ immunology
Biomarkers
CD4-Positive T-Lymphocytes
/ immunology
Disease Management
Disease Models, Animal
Disease Susceptibility
Gene Expression
Gene Expression Regulation, Neoplastic
Histocompatibility Antigens Class I
/ genetics
Histocompatibility Antigens Class II
/ genetics
Humans
Immunotherapy
Neoplasms
/ etiology
Signal Transduction
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 04 2019
15 04 2019
Historique:
received:
28
09
2018
revised:
02
10
2018
accepted:
16
11
2018
pubmed:
23
11
2018
medline:
30
5
2020
entrez:
23
11
2018
Statut:
ppublish
Résumé
Immunotherapy has emerged as a key pillar of cancer treatment. To build upon the recent successes of immunotherapy, intense research efforts are aimed at a molecular understanding of antitumor immune responses, identification of biomarkers of immunotherapy response and resistance, and novel strategies to circumvent resistance. These studies are revealing new insight into the intricacies of tumor cell recognition by the immune system, in large part through MHCs. Although tumor cells widely express MHC-I, a subset of tumors originating from a variety of tissues also express MHC-II, an antigen-presenting complex traditionally associated with professional antigen-presenting cells. MHC-II is critical for antigen presentation to CD4
Identifiants
pubmed: 30463850
pii: 1078-0432.CCR-18-3200
doi: 10.1158/1078-0432.CCR-18-3200
pmc: PMC6467754
mid: NIHMS1512930
doi:
Substances chimiques
Biomarkers
0
Histocompatibility Antigens Class I
0
Histocompatibility Antigens Class II
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2392-2402Subventions
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA181491
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007347
Pays : United States
Informations de copyright
©2018 American Association for Cancer Research.
Références
Glia. 2001 Dec;36(3):391-405
pubmed: 11746775
Cell. 2002 Apr;109 Suppl:S21-33
pubmed: 11983150
J Hematol Oncol. 2016 May 27;9(1):47
pubmed: 27234522
Cancer Res. 2010 Nov 1;70(21):8368-77
pubmed: 20940398
J Exp Med. 1998 Mar 2;187(5):693-702
pubmed: 9480979
Immunity. 1998 Feb;8(2):157-66
pubmed: 9491997
Ann N Y Acad Sci. 1988;532:51-60
pubmed: 2460011
Immunol Rev. 2009 May;229(1):126-44
pubmed: 19426219
Tumour Biol. 2001 Sep-Oct;22(5):294-8
pubmed: 11553859
Immunol Cell Biol. 1997 Aug;75(4):325-32
pubmed: 9315472
J Immunol. 2012 May 15;188(10):4951-8
pubmed: 22490869
J Immunol. 2015 Mar 1;194(5):2049-56
pubmed: 25710958
J Immunol. 2002 Jul 15;169(2):739-49
pubmed: 12097376
Cancer Res. 2018 Aug 15;78(16):4573-4585
pubmed: 29752262
Eur J Immunol. 2003 May;33(5):1183-92
pubmed: 12731043
Clin Cancer Res. 2018 Nov 1;24(21):5250-5260
pubmed: 30021908
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Mol Immunol. 2019 Sep;113:16-21
pubmed: 29224918
Int J Cancer. 2010 Oct 1;127(7):1614-24
pubmed: 20091859
Cancer Res. 1998 Apr 1;58(7):1486-93
pubmed: 9537252
Cell. 2018 Dec 13;175(7):1991
pubmed: 30550793
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Cancer Immunol Immunother. 1995 Jan;40(1):1-9
pubmed: 7828162
Immunity. 1997 May;6(5):601-11
pubmed: 9175838
PLoS One. 2014 Jan 27;9(1):e87377
pubmed: 24475282
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Cancer Immunol Immunother. 2019 Feb;68(2):175-188
pubmed: 30334128
Science. 1994 Jul 1;265(5168):106-9
pubmed: 8016643
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Mol Immunol. 2018 Jul;99:163-170
pubmed: 29787980
Prostate Cancer Prostatic Dis. 2008;11(4):334-41
pubmed: 17938645
Nat Rev Immunol. 2014 Nov;14(11):719-30
pubmed: 25324123
Eur J Immunogenet. 1995 Aug;22(4):299-310
pubmed: 7495782
Cell Rep. 2017 Jul 18;20(3):558-571
pubmed: 28723561
Clin Cancer Res. 2008 Dec 1;14(23):7667-73
pubmed: 19047092
J Immunol. 1996 May 15;156(10):3821-7
pubmed: 8621919
Mol Cancer. 2015 Feb 15;14:41
pubmed: 25744203
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
J Immunother. 1998 May;21(3):218-24
pubmed: 9610914
Curr Opin Immunol. 2015 Jun;34:22-7
pubmed: 25597442
J Clin Invest. 2018 Apr 2;128(4):1563-1568
pubmed: 29360643
Eur J Immunol. 2007 Mar;37(3):788-97
pubmed: 17304627
J Immunol. 1990 May 15;144(10):4068-71
pubmed: 2332639
Curr Opin Immunol. 2002 Feb;14(1):30-5
pubmed: 11790530
Oncoimmunology. 2016 Nov 28;6(1):e1261777
pubmed: 28197387
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Nature. 2011 Mar 17;471(7338):377-81
pubmed: 21368758
J Immunol. 1998 Jul 15;161(2):814-20
pubmed: 9670958
Hum Pathol. 2012 Sep;43(9):1394-9
pubmed: 22401771
J Immunol. 1992 Oct 1;149(7):2391-6
pubmed: 1527384
Cancer Immunol Immunother. 1996 Feb;42(2):99-107
pubmed: 8620527
Int Immunol. 2006 Nov;18(11):1591-602
pubmed: 16987935
Cell Rep. 2015 Nov 17;13(7):1418-1431
pubmed: 26549456
Nat Commun. 2016 Jan 29;7:10582
pubmed: 26822383
Cell Growth Differ. 2001 Jun;12(6):327-35
pubmed: 11432807
Sci Transl Med. 2016 Sep 7;8(355):355ra116
pubmed: 27605551
Immunity. 1997 May;6(5):591-600
pubmed: 9175837
Oncogene. 1994 Apr;9(4):1015-9
pubmed: 8134104
Cancer Res. 2016 May 15;76(10):2921-31
pubmed: 27020860
J Exp Med. 1994 Oct 1;180(4):1367-74
pubmed: 7931070
Annu Rev Immunol. 2016 May 20;34:265-97
pubmed: 26907214
Mol Cell Biol. 1999 Jan;19(1):431-40
pubmed: 9858567
EMBO J. 1997 May 15;16(10):2851-60
pubmed: 9184229
Mol Cell Biol. 2000 Sep;20(17):6185-94
pubmed: 10938095
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91
pubmed: 9192661
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
Cancer Immunol Res. 2013 Oct;1(4):235-44
pubmed: 24396833
PLoS One. 2017 Aug 23;12(8):e0183594
pubmed: 28832681
J Exp Med. 2010 Mar 15;207(3):651-67
pubmed: 20156973
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3435-43
pubmed: 16740768
Nat Immunol. 2014 Nov;15(11):1070-8
pubmed: 25263123
Cell. 1996 Feb 9;84(3):431-42
pubmed: 8608597
Oncotarget. 2017 Jul 4;8(27):44159-44170
pubmed: 28498806
Nat Rev Immunol. 2016 Feb;16(2):102-11
pubmed: 26781939
Front Immunol. 2014 Apr 15;5:174
pubmed: 24782871
Br J Cancer. 1987 Dec;56(6):727-33
pubmed: 3435699
Clin Cancer Res. 2011 May 1;17(9):2619-27
pubmed: 21372217
J Exp Med. 1993 Jun 1;177(6):1699-712
pubmed: 8098731
Science. 2003 Apr 11;300(5617):339-42
pubmed: 12690202
J Immunol. 1999 Jun 1;162(11):6663-70
pubmed: 10352284
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Immunity. 2016 Oct 18;45(4):917-930
pubmed: 27760342
PLoS One. 2017 Aug 17;12(8):e0182786
pubmed: 28817603
Int J Cancer. 1990 Jun 15;45(6):1169-76
pubmed: 2112515
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cancer Immunol Res. 2014 Feb;2(2):91-8
pubmed: 24778273
Nat Rev Immunol. 2015 Apr;15(4):203-16
pubmed: 25720354
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
Cancer Immunol Res. 2016 Oct;4(10):845-857
pubmed: 27589875
J Immunogenet. 1989 Aug-Oct;16(4-5):343-9
pubmed: 2639907
Int J Cancer. 1995 Aug 9;62(4):461-5
pubmed: 7635572
J Immunol. 2002 Nov 1;169(9):5061-71
pubmed: 12391222
J Immunol. 1996 Apr 1;156(7):2495-502
pubmed: 8786310
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
Trends Genet. 1993 Apr;9(4):117-22
pubmed: 8516845
Front Immunol. 2011 Oct 04;2:48
pubmed: 22566838
Int Immunol. 2013 Apr;25(4):235-46
pubmed: 23334921
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Nature. 2003 Feb 20;421(6925):852-6
pubmed: 12594515
J Immunol. 2007 Oct 15;179(8):5317-25
pubmed: 17911618
Am J Pathol. 2002 Jul;161(1):291-300
pubmed: 12107114
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Clin Cancer Res. 2016 Mar 15;22(6):1499-509
pubmed: 26515496
J Clin Oncol. 2018 Apr 1;36(10):942-950
pubmed: 29394125
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Pathol. 1999 Jan;187(2):191-9
pubmed: 10365094
EMBO J. 1996 Jan 15;15(2):418-28
pubmed: 8617217
JAMA Oncol. 2017 Aug 01;3(8):1051-1058
pubmed: 28278348
Front Immunol. 2013 Aug 29;4:260
pubmed: 24009612
J Exp Med. 2012 Oct 22;209(11):2113-26
pubmed: 23008334
Clin Transl Immunology. 2017 Oct 20;6(10):e160
pubmed: 29114389
Cell. 2017 Jan 26;168(3):487-502.e15
pubmed: 28111070
J Immunol. 1998 Apr 1;160(7):3363-73
pubmed: 9531296
J Clin Pathol. 2000 Apr;53(4):286-91
pubmed: 10823125
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Cancer Immunol Res. 2016 May;4(5):390-9
pubmed: 26980599
J Heart Lung Transplant. 2002 Aug;21(8):882-9
pubmed: 12163088
Int J Cancer. 2004 Nov 10;112(3):399-406
pubmed: 15382064
Int J Cancer. 2010 Aug 15;127(4):889-98
pubmed: 20013806
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
J Immunol. 2001 Jul 1;167(1):98-106
pubmed: 11418637
N Engl J Med. 2008 Jun 19;358(25):2698-703
pubmed: 18565862
Int J Breast Cancer. 2013;2013:250435
pubmed: 24363939
Exp Mol Med. 2011 May 31;43(5):281-90
pubmed: 21464590